Compare Campbell Soup Co. (CPB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Mesoblast Limited — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.64B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Campbell Soup Co. is far larger — about 3.1× Mesoblast Limited's market cap, and Campbell Soup Co. pays a 5.29% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Mesoblast Limited for 14 Days on average.
| CPB | MESO | |
|---|---|---|
Market Cap | $5.64B | $1.81B |
Volume | 8,200,811 | 240,620 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $20.96 |
52-Week Low | $18.90 | $13.19 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $12.70B | $1.89B |
Dividend Yield | 5.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $19.37, up 1.95% on the day, with a bearish technical outlook and mixed fundamentals. Recent Q4 2026 earnings missed expectations, while the company implemented a 36% dividend cut and announced a $500 million cost-savings plan. Valuation metrics appear reasonable with P/E of 14.44 and P/S of 0.58, but profit margins have declined from 9.16% in 2023 to 4.13% projected for 2026.
The outlook remains challenging with declining profitability and bearish analyst sentiment, though current valuation may offer value for patient investors. Key risks include ongoing margin pressure, competitive threats, and execution of the turnaround plan. With only 6.9% of analysts rating it Buy, the stock faces significant headwinds despite trading near consensus price target of $19.67.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
